Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2025 Apr 1.

Published in final edited form as: JCO Precis Oncol. 2024 Apr;8:e2300567. doi: 10.1200/PO.23.00567

Figure 3. — (A) Oncoprint showing actionable items found on subsequent NGS testing (second NGS and beyond) and treatments given after the second NGS test result. Actionable is a composite of BRCA1/2 alterations, non-BRCA HRR alterations, microsatellite instability (MSI-high) and mismatch repair deficiency (MMRd), and high tumor mutational burden ≥ 10 mut/MB (TMB). (B) The number of NGS tests that showed a gene alteration (left), each gene’s detection frequency (right), and detection frequency for TMB, MSI-high, and MMRd, color coded by NGS test number.

Figure 3. — (A) Oncoprint showing actionable items found on subsequent NGS testing (second NGS and beyond) and treatments given after the second NGS test result. Actionable is a composite of BRCA1/2 alterations, non-BRCA HRR alterations, microsatellite instability (MSI-high) and mismatch repair deficiency (MMRd), and high tumor mutational burden ≥ 10 mut/MB (TMB). (B) The number of NGS tests that showed a gene alteration (left), each gene’s detection frequency (right), and detection frequency for TMB, MSI-high, and MMRd, color coded by NGS test number.